NPC 17923

Drug Profile

NPC 17923

Latest Information Update: 16 Jul 1998

Price : $50

At a glance

  • Originator Scios
  • Class Aminobenzoic acids; Anti-inflammatories; Antirheumatics; Fluorenes; Small molecules
  • Mechanism of Action Immunosuppressants; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 16 Jul 1998 No-Development-Reported for Ulcerative colitis in USA (Unknown route)
  • 16 Jul 1998 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)
  • 01 Jun 1995 Preclinical development for Ulcerative colitis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top